Dr Sam Roberts

Chief Executive, National Institute for Health
and Care Excellence (NICE), UK

Dr Roberts is the Chief Executive of the National Institute for Health and Care Excellence. She has worked in healthcare for 20 years in a combination of clinical, operational, private sector and academic roles. She originally trained as a doctor before undertaking an MBA and joining McKinsey and Company. Her focus for the last 15 years has been on improving quality of clinical care and supporting uptake of innovation - as Head of Operations at a large teaching hospital in London (UCLH), Director of Innovation, Research and Life Sciences at NHS England and Improvement and Chief Executive of the Accelerated Access Collaborative. Prior to joining NICE, she invested in early-stage digital health and diagnostics companies. She has an academic interest in the influence of health economic analysis on policy and clinical practice, having worked at the London School of Economics followed by doctoral studies at the University of Oxford.


Professor Dean Ho

Provost's Chair Professor;
Head, Department of Biomedical Engineering
Director, The N.1 Institute for Health (N.1);
Director, The Institute for Digital Medicine (WisDM),
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore (NUS)

Professor Ho leads a pre-eminent team with over 10 technology platforms in human clinical trials. He is a Subgroup Lead in the World Health Organization (WHO) AI for Health Regulatory Working Group and was elected to the National Academy of Inventors (NAI), American Association for the Advancement of Science (AAAS), and American Institute for Medical and Biological Engineering (AIMBE).

Professor Ho co-authored the best-selling book, Medicine Without Meds. His work has been featured in the Straits Times, CNA, National Geographic, CNN, and The Economist. He has been a plenary and keynote speaker at major global technology, economics, and policy forums.

Professor Patrick Tan

Executive Director, Precision Health
Research, Singapore (PRECISE)

Professor Tan is the Executive Director of PRECISE. As Executive Director of PRECISE, Prof Tan oversees the implementation of Phase II of Singapore’s Precision Medicine programme, which aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions.

Prof Tan is also Senior Vice Dean (Research) at Duke-NUS Medical School and Chief Scientific Officer at the Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR).

During the 2020 COVID-19 pandemic, he was Program Director of Operation Stronghold, establishing one of Singapore’s largest COVID-19 testing facilities through a joint effort involving A*STAR, National University Health System, and Temasek Holdings.

Professor Pearse Keane

Professor of Artificial Medical Intelligence,
University College London
Consultant Ophthalmologist, Moorfields Eye
Hospital NHS Foundation Trust

Professor Keane MD FRCOphth is Professor of Artificial Medical Intelligence at UCL Institute of Ophthalmology, and a consultant ophthalmologist at Moorfields Eye Hospital, London. Since 2020, he has been funded by UK Research & Innovation (UKRI) as a Future Leaders Fellow, and in 2023 he became a National Institute for Health Research (NIHR) Senior Investigator. He is originally from Ireland and received his medical degree from University College Dublin (UCD), graduating in 2002.

In 2016, he initiated a collaboration between Moorfields Eye Hospital and Google DeepMind, with the aim of developing artificial intelligence (AI) algorithms for the earlier detection and treatment of retinal disease. In August 2018, the first results of this collaboration were published in the journal, Nature Medicine. In May 2020, he jointly led work, again published in Nature Medicine, to develop an early warning system for age-related macular degeneration (AMD), by far the commonest cause of blindness in many countries. In 2023, he led the development of RETFound, the first foundation model in ophthalmology, published in Nature and made available open source.

In October 2019, he was included on the Evening Standard Progress1000 list of most influential Londoners and in June 2020, he was profiled in The Economist.

In 2022, he was listed in the “Top 10” of the “The Power List” by The Ophthalmologist magazine, a ranking of the Top 100 most influential people in the world of ophthalmology.

Professor Tim Shaw

Professor of eHealth and Director of Research in Implementation Science and eHealth (RISe),
Charles Perkins Centre, School of Medical Sciences;
Principal Investigator, Westmead Applied Research Centre,
University of Sydney

Professor Shaw is Director of the Research in eHealth and Implementation Science Group (RISe) in the School of Medical Sciences at The University of Sydney. He specialises in building partnerships across industry, services, government, communities and academia to deliver high impact research translation. His research focuses on how digital health can support new models of care as well as clinical decision support. Over the last 5 years, he has been a Chief Investigator on over 30 competitive or commissioned research and development projects totalling over $124M. He is Flagship Research and Education Director and led the successful bid for the $110M Digital Health Cooperative Research Centre.

Professor Toh Han Chong

Deputy CEO (Strategic Partnerships);
Senior Consultant, Division of Medical Oncology,
National Cancer Centre Singapore (NCCS)

Professor Toh is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at the Duke NUS Medical School. He obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and research training were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Prof. Toh is an alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the SingHealth Duke NUS Cell Therapy Centre. Prof. Toh is a council member at the Singapore Ministry of Health Agency for Care Effectiveness (ACE) and member of the Ministry of Health Clinical Services Strategy Committee for Cell Therapy.

Prof. Toh is recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer. He leads the NMRC Large Collaborative Grant VICTORY (Virus-Induced Cancers Translational Oncology and immunology) grant and is recipient of the NMRC STaR Award 2022 focusing on the translational understanding and therapeutic development for viral and non-viral hepatocellular carcinoma.

Prof. Toh is European Society for Medical Oncology (ESMO) faculty for Cancer Immunology and on the ESMO Scientific Committee 2024. He is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS). He has published over 150 peer review journal papers.